UK biotechs suffered restricted financing in 2025
Both the amount of equity financing and venture capital attracted by UK biotechs dropped in 2025, compounding concerns for the …
Post
-
-
MSD ends takeover talks with Revolution Medicines
Merck & Co (MSD) is no longer in talks to acquire oncology biotech Revolution Medicines after negotiations hit a stumbling …
-
NICE greenlights Pfizer’s Talzenna for NHS use
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Talzenna (talazoparib) in a step forward for …
-
Corxel raises $287m as obesity continues to spark investor interest
Corxel Pharmaceuticals has raised $287m to fund its suite of cardiometabolic assets, signifying that investor appetite for weight loss drug …
-
High-dose biologic delivery to become industry standard
As the pharmaceutical industry progresses further into the age of personalised medicine, next-generation, targeted and disease-modifying biologics are becoming increasingly …
-
Daiichi Sankyo and AstraZeneca’s Enhertu gains NMPA approval for HER2 GEJ
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has received approval from China’s National Medical Products Administration (NMPA) for adults with …
-
BMS bets on Janux’s novel solid tumour therapy through $850m deal
Bristol Myers Squibb (BMS) has added to its oncology pipeline through an exclusive global licensing agreement with Janux Therapeutics. This deal …
-
US set to officially exit WHO in culmination of Trump’s domestic push
The US is poised to leave the World Health Organization (WHO) as the one-year countdown of legal notice comes to …
-
The new safety mandate driving AI-ready pharmacovigilance
Regulatory expectations in the drug safety industry have evolved faster in the past five years than in the previous two …
-
Heart disease and stroke deaths take a downturn, AHA report reveals
A new report from the American Heart Association (AHA) has found that US cardiovascular disease (CVD)-related deaths declined between 2022 …
-
Johnson & Johnson reports 9.1% increase in sales for Q4 2025
Johnson & Johnson (J&J) has reported a 9.1% increase in sales for Q4 2025, reaching $24.56bn, with net earnings rising …
-
Opna Bio’s OPN-2853 secures FDA’s orphan drug status for myelofibrosis
Opna Bio has received the US Food and Drug Administration’s (FDA) orphan drug designation for OPN-2853 (zavabresib), a bromodomain and …
-
Davos26: Trump says tariff threats helped fix US drug pricing ‘unfairness’
The threat of tariffs was necessary to get major drugmakers and foreign leaders on board with drug pricing reforms in …
-
Walking the pharma supply chain tightrope requires more than precision
Between 2023 and 2025, hundreds of thousands of Type 2 diabetes patients were unable to access semaglutide due to off-label …
-
Free webinar: Ensuring compliance-first logistics for reliable clinical trials
According to GlobalData, industry-sponsored trials have increased from 7,721 in 2016 to 13, 685 in 2025. This growth over the …
